Keryx Biopharmaceuticals is restructuring in an effort to reduce its cash burn rate and re-focus its development efforts. The restructuring plan, which follows the negative outcome of the company’s Phase III trial of Sulonex for the treatment of diabetic nephropathy, and subsequent decision to terminate the ongoing Phase IV trial, is intended to conserve financial resources and to focus efforts on programs and opportunities that are most likely to provide long-term shareholder value.     ...